Related Experiment Videos
Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H
J D Isaacs1, B L Hazleman, K Chakravarty
1Department of Rheumatology, Addenbrooke's NHS Trust, Cambridge, UK.
The Journal of Rheumatology
|June 1, 1996
Abstract:
A worker in a polyvinyl chloride factory with rapidly progressive diffuse cutaneous scleroderma was treated with the humanized monoclonal antibody (Mab) CAMPATH-1H. Treatment was followed by rapid and substantial improvement in skin score, which was maintained during followup without additional therapy. The mode of action of CAMPATH-1H and its relationship to clinical improvement are discussed.